[acqua+]

Questo è veramente un titolo di ,,, spessore

Okkio alla bestia

Ora 1,30


http://www.hgsi.com/



Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

[acqua+]

PIPELINE


http://www.hgsi.com/products.html

[acqua+]

fresca, fresca ,,,


http://finance.yahoo.com/news/Human-...2616.html?.v=1

[acqua+]

[acqua+]

UPDATE 1-Human Genome Sciences posts Q1 profit; shares rise


http://www.reuters.com/article/marke...0090429?rpc=44


After Hours: 1.74 0.35 (25.18%) 7:25PM ET

[acqua+]

gran bei volumi



Last Trade:1.74 Change: 0.35 (25.18%) 1y Target Est:3.21

Volume:6,301,785 Avg Vol (3m):3,218,310

[Netzach]

Che dire ... le avevo e sono stato " disturbato " nel tenerle ...

Il nostro "ciofecone" invece è sempre fermo ...

Speriamo che non sia la "Bella di Torriglia" che tutti la vogliono, ma nessuno la piglia ...

[acqua+]

chiusura IMPRESSIONANTE !!!!!


Last Trade:2.19 ETChange: 0.80 (57.55%) Prev Close:1.39

Volume: 14,502,322 Avg Vol (3m): 3,218,310Market Cap:297.28M

[acqua+]

http://finance.yahoo.com/news/Human-...2998.html?.v=1

[coxy]

Genetic fusion. costruire fusioni tra albumina ed il peptide proteina di interesse. Stabilizzare il peptide/proteina di interesse, facilitare il delivery alle cellule bersaglio.
Non male, ma sarebbe cosa ben superiore aggiungere, sempre via genetic fusion, anche motivi che aumentino la specificità di interazione con il target cellulare.
ovviamente dopo aver scelto un numero ristretto di candidati.
ci vorrà molto tempo, da seguire.